Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleInflammation, Immunopharmacology, and Asthma

Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis

Stefania Petrosino, Roberta Verde, Massimo Vaia, Marco Allarà, Teresa Iuvone and Vincenzo Di Marzo
Journal of Pharmacology and Experimental Therapeutics June 2018, 365 (3) 652-663; DOI: https://doi.org/10.1124/jpet.117.244368
Stefania Petrosino
Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Napoli, Italy (S.P., R.V., M.A., V.D.); Epitech Group SpA, Saccolongo, Padova, Italy (S.P., M.A.); and Dipartimento di Farmacologia Sperimentale, Università di Napoli “Federico II”, Napoli, Italy (M.V., T.I.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberta Verde
Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Napoli, Italy (S.P., R.V., M.A., V.D.); Epitech Group SpA, Saccolongo, Padova, Italy (S.P., M.A.); and Dipartimento di Farmacologia Sperimentale, Università di Napoli “Federico II”, Napoli, Italy (M.V., T.I.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Vaia
Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Napoli, Italy (S.P., R.V., M.A., V.D.); Epitech Group SpA, Saccolongo, Padova, Italy (S.P., M.A.); and Dipartimento di Farmacologia Sperimentale, Università di Napoli “Federico II”, Napoli, Italy (M.V., T.I.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Allarà
Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Napoli, Italy (S.P., R.V., M.A., V.D.); Epitech Group SpA, Saccolongo, Padova, Italy (S.P., M.A.); and Dipartimento di Farmacologia Sperimentale, Università di Napoli “Federico II”, Napoli, Italy (M.V., T.I.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Iuvone
Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Napoli, Italy (S.P., R.V., M.A., V.D.); Epitech Group SpA, Saccolongo, Padova, Italy (S.P., M.A.); and Dipartimento di Farmacologia Sperimentale, Università di Napoli “Federico II”, Napoli, Italy (M.V., T.I.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincenzo Di Marzo
Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Napoli, Italy (S.P., R.V., M.A., V.D.); Epitech Group SpA, Saccolongo, Padova, Italy (S.P., M.A.); and Dipartimento di Farmacologia Sperimentale, Università di Napoli “Federico II”, Napoli, Italy (M.V., T.I.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    CBD reduces MCP-2 levels in poly-(I:C)–stimulated HaCaT cells. Enzyme-linked immunosorbent assay for MCP-2 release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml) in the presence of vehicle or CBD (1, 5, 10, and 20 μM) for 6 (A), 12 (B), and 24 hours (C) at 37°C in 5% CO2. Data represent the mean ± S.E.M. of three independent experiments performed in triplicate. §§§P < 0.001 vs. vehicle; ***P < 0.001 vs. poly-(I:C). Assay range for MCP-2, 0.8–200 pg/ml.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    CBC, CBG, THCV, and CBGV reduce MCP-2 levels in poly-(I:C)–stimulated HaCaT cells. Enzyme-linked immunosorbent assay for MCP-2 release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 6 hours, 37°C) in the presence of vehicle or CBC (A), CBG (B), THCV (C), and CBGV (D) (all tested at 5, 10, and 20 μM). Data represent the mean ± S.E.M. of three independent experiments performed in triplicate. §§§P < 0.001 vs. vehicle; **P < 0.01; ***P < 0.001 vs. poly-(I:C). Assay range for MCP-2, 0.8–200 pg/ml.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    CBD reduces IL-6, IL-8, and TNF-α levels in poly-(I:C)–stimulated HaCaT cells after 6 hours. Bio-Plex Pro assay for IL-6 (A), IL-8 (B), and TNF-α (C) release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 6 hours, 37°C) in the presence of vehicle or CBD (1, 5, 10, and 20 μM). Data represent the mean ± S.E.M. of three independent experiments performed in triplicate. §§§ P < 0.001 vs. vehicle; *P < 0.05; ***P < 0.001 vs. poly-(I:C). Assay range for IL-6, 37.68 pg/ml; for IL-8, 42.15 pg/ml; and for TNF-α, 64.80 pg/ml.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    CBD reduces IL-6 and TNF-α levels in poly-(I:C)–stimulated HaCaT cells after 12 and 24 hours. (A) Bio-Plex Pro assay for TNF-α release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 12 hours, 37°C) in the presence of vehicle or CBD (20 μM). Bio-Plex Pro assay for IL-6 (B) and TNF-α (C) release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 24 hours, 37°C) in the presence of vehicle or CBD (20 μM). Data represent the mean ± S.E.M. of three independent experiments performed in triplicate. §§§P < 0.001 vs. vehicle; ***P < 0.001 vs. poly-(I:C). Assay range for IL-6, 37.68 pg/ml; and for TNF-α, 64.80 pg/ml.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    CBC, CBG, and THCV reduce IL-6 and IL-8 levels in poly-(I:C)–stimulated HaCaT cells after 6 hours. Bio-Plex Pro assay for IL-6 (A, C, and E) and IL-8 (B and D) release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 6 hours, 37°C) in the presence of vehicle or CBC, CBG, and THCV (all tested at 5, 10, and 20 μM). Data represent the mean ± S.E.M. of three independent experiments performed in triplicate. §§§P < 0.001 vs. vehicle; *P < 0.05; **P < 0.01; ***P < 0.001 vs. poly-(I:C). Assay range for IL-6, 37.68 pg/ml; and for IL-8, 42.15 pg/ml.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    CBD and other phytocannabinoids are not cytotoxic in HaCaT cells. (A) MTT assay in HaCaT cells treated with vehicle (white histogram) or CBD, CBC, CBG, THCV, and CBGV (all tested at 10 and 20 μM) for 6 hours at 37°C in 5% CO2. (B) MTT assay in HaCaT cells treated with vehicle or CBD (10 and 20 μM) for 12 and 24 hours at 37°C in 5% CO2. Data represent the mean ± S.E.M. of three independent experiments performed in triplicate.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    CB2 and TRPV1 receptors mediate the action of CBD in poly-(I:C)–stimulated HaCaT cells after 6 hours. (A) Enzyme-linked immunosorbent assay for MCP-2 release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 6 hours, 37°C) treated with AM251 (1, 2.5, and 5 μM) in the presence or absence of CBD (20 μM). (B) Enzyme-linked immunosorbent assay for MCP-2 release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 6 hours, 37°C) treated with AM630 (0.01 and 0.1 μM) or I-RTX (0.01 and 0.1 μM) in the presence or absence of CBD (20 μM). Data represent the mean ± S.E.M. of three independent experiments performed in triplicate. §§§P < 0.001 vs. vehicle. ***P < 0.001; **P < 0.01 vs. poly-(I:C); °°P < 0.01; °°°P < 0.001 vs. poly-(I:C) + CBD 20 μM. Assay range for MCP-2, 0.8–200 pg/ml.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    CBD elevates AEA levels in poly-(I:C)–stimulated HaCaT cells after 6 hours. Concentrations of AEA (A), 2-AG (B), PEA (C), and OEA (D) in poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 6 hours, 37°C) in the presence of vehicle or CBD (20 μM). Data represent the mean ± S.E.M. of three independent experiments performed in triplicate. ***P < 0.001 vs. vehicle; °°°P < 0.001 vs. poly-(I:C) + vehicle.

  • Fig. 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 9.

    AEA and URB597 reduce MCP-2, IL-6, and IL-8 levels in poly-(I:C)–stimulated HaCaT cells after 6 hours. Enzyme-linked immunosorbent assay for MCP-2 (A) and Bio-Plex Pro assay for IL-6 (B) and IL-8 (C) release in the supernatants of poly-(I:C)–stimulated HaCaT cells (100 μg/ml, 6 hours, 37°C) in the presence of vehicle or CBD (20 μM), AEA (10 μM), or URB597 (10 μM). Data represent the mean ± S.E.M. of three independent experiments performed in triplicate. §§§P < 0.001 vs. vehicle; *P < 0.05; **P < 0.01; ***P < 0.001 vs. poly-(I:C). Assay range for MCP-2, 0.8–200 pg/ml; for IL-6, 37.68 pg/ml; and for IL-8, 42.15 pg/ml.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 365 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 365, Issue 3
1 Jun 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleInflammation, Immunopharmacology, and Asthma

Cannabidiol and Allergic Contact Dermatitis

Stefania Petrosino, Roberta Verde, Massimo Vaia, Marco Allarà, Teresa Iuvone and Vincenzo Di Marzo
Journal of Pharmacology and Experimental Therapeutics June 1, 2018, 365 (3) 652-663; DOI: https://doi.org/10.1124/jpet.117.244368

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleInflammation, Immunopharmacology, and Asthma

Cannabidiol and Allergic Contact Dermatitis

Stefania Petrosino, Roberta Verde, Massimo Vaia, Marco Allarà, Teresa Iuvone and Vincenzo Di Marzo
Journal of Pharmacology and Experimental Therapeutics June 1, 2018, 365 (3) 652-663; DOI: https://doi.org/10.1124/jpet.117.244368
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Expression of PAR2 in iKera to Model Atopic Dermatitis
  • PK/PD of Dexamethasone in LPS-Challenged Rats
  • Cholesterol Esterification and Acute Lung Injury
Show more INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics